Verona Pharma Plc Company Profile (LON:VRP)

About Verona Pharma Plc (LON:VRP)

Verona Pharma Plc logoVerona Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. The Company's product candidate, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4) that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The Company is developing RPL554 in a nebulized formulation for the maintenance treatment of COPD patients and for the treatment of cystic fibrosis. It also is developing RPL554 as an add-on therapy to commonly used therapies for the treatment of acute exacerbations of COPD in the hospital setting. In addition to its nebulized formulation of RPL554, the Company is developing RPL554 in both dry powder inhaler (DPI) and metered dose inhaler (MDI) formulations for the maintenance treatment of COPD.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: LON:VRP
  • CUSIP: N/A
  • Web: www.veronapharma.com/
Capitalization:
  • Market Cap: £124.36 million
  • Outstanding Shares: 88,516,000
Average Prices:
  • 50 Day Moving Avg: GBX 126.20
  • 200 Day Moving Avg: GBX 130.85
  • 52 Week Range: GBX 100 - GBX 210
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: GBX 1.05 per share
  • Price / Book: 1.34
Profitability:
  • EBIDTA: ($15,990,000.00)
Misc:
  • Average Volume: 53,148 shs.
 

Frequently Asked Questions for Verona Pharma Plc (LON:VRP)

What is Verona Pharma Plc's stock symbol?

Verona Pharma Plc trades on the London Stock Exchange (LON) under the ticker symbol "VRP."

Where is Verona Pharma Plc's stock going? Where will Verona Pharma Plc's stock price be in 2017?

4 brokers have issued 1 year price objectives for Verona Pharma Plc's stock. Their forecasts range from GBX 22 to GBX 250. On average, they expect Verona Pharma Plc's stock price to reach GBX 80.75 in the next year. View Analyst Ratings for Verona Pharma Plc.

Who are some of Verona Pharma Plc's key competitors?

Who are Verona Pharma Plc's key executives?

Verona Pharma Plc's management team includes the folowing people:

  • Sven Jan-Anders Karlsson, Chief Executive Officer, Executive Director
  • Kenneth B. Newman M.D., Chief Medical Officer
  • Ben Harber, Company Secretary
  • David Raymond Ebsworth Ph.D., Non-Executive Chairman of the Board
  • Kenneth D. Cunningham M.D., Non-Executive Director
  • Vikas Sinha CPA, Non-Executive Director
  • Anders Ullman M.D., Ph.D., Non-Executive Director

How do I buy Verona Pharma Plc stock?

Shares of Verona Pharma Plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Verona Pharma Plc's stock price today?

One share of Verona Pharma Plc stock can currently be purchased for approximately GBX 140.50.


MarketBeat Community Rating for Verona Pharma Plc (LON VRP)
Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  65 (Vote Outperform)
Underperform Votes:  115 (Vote Underperform)
Total Votes:  180
MarketBeat's community ratings are surveys of what our community members think about Verona Pharma Plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Verona Pharma Plc (LON:VRP) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: GBX 80.75

Analysts' Ratings History for Verona Pharma Plc (LON:VRP)
Show:
DateFirmActionRatingPrice TargetDetails
6/27/2017N+1 SingerReiterated RatingcorporateView Rating Details
6/9/2017Jefferies Group LLCReiterated RatingBuyGBX 250View Rating Details
5/22/2017WedbushInitiated CoverageOutperformGBX 25View Rating Details
5/22/2017SunTrust Banks, Inc.Initiated CoverageBuyGBX 26View Rating Details
5/22/2017Stifel NicolausInitiated CoverageBuyGBX 22View Rating Details
(Data available from 9/21/2015 forward)

Earnings

Earnings History for Verona Pharma Plc (LON:VRP)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Verona Pharma Plc (LON:VRP)
Current Year EPS Consensus Estimate: $-38.15 EPS

Dividends

Dividend History for Verona Pharma Plc (LON:VRP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Verona Pharma Plc (LON:VRP)
Insider Trades by Quarter for Verona Pharma Plc (LON:VRP)
Insider Trades by Quarter for Verona Pharma Plc (LON:VRP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/27/2017David EbsworthInsiderBuy177,776GBX 169£300,441.44
4/26/2017David EbsworthInsiderBuy13,373GBX 132£17,652.36
3/1/2017Sven Jan-Anders KarlssonInsiderBuy7,750GBX 149£11,547.50
2/28/2017Sven Jan-Anders KarlssonInsiderBuy12,000GBX 149£17,880
8/9/2016Jan-Anders Karlsson,SvenInsiderBuy600,000GBX 3£18,000
1/20/2016Ebsworth,DavidInsiderBuy400,000GBX 3£12,000
12/3/2015Ebsworth,DavidInsiderBuy370,000GBX 3£11,100
6/17/2015David EbsworthInsiderBuy250,000GBX 4.70£11,750
5/18/2015David EbsworthInsiderBuy300,000GBX 3.50£10,500
3/3/2015David EbsworthInsiderBuy450,000GBX 2.43£10,935
2/16/2015Biresh RoyInsiderBuy500,000GBX 2.30£11,500
2/13/2015Sven Jan-Anders KarlssonInsiderBuy1,025,909GBX 2£20,518.18
2/4/2015David EbsworthInsiderBuy700,000GBX 1.54£10,780
1/19/2015Stuart BottomlyInsiderBuy1,000,000GBX 1.50£15,000
1/13/2015David EbsworthInsiderBuy803,107GBX 1.35£10,841.94
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Verona Pharma Plc (LON:VRP)
Latest Headlines for Verona Pharma Plc (LON:VRP)
Source:
DateHeadline
finance.yahoo.com logoCan Verona Pharma plc (AIM:VRP) Improve Your Portfolio Returns?
finance.yahoo.com - September 13 at 11:02 AM
globenewswire.com logoArix Bioscience plc notes positive trial data from Verona Pharma in COPD
globenewswire.com - September 7 at 11:01 AM
finance.yahoo.com logoVerona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva®)
finance.yahoo.com - September 7 at 11:01 AM
finance.yahoo.com logoVerona Pharma Appoints Stifel as Nominated Adviser
finance.yahoo.com - September 1 at 10:55 AM
finance.yahoo.com logoEdited Transcript of VRP.L earnings conference call or presentation 8-Aug-17 12:00pm GMT
finance.yahoo.com - August 11 at 3:55 PM
americanbankingnews.com logoVerona Pharma Plc (LON:VRP) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - August 3 at 8:10 PM
finance.yahoo.com logoVerona Pharma to Announce Interim Results for Six Months Ended June 30, 2017 and Provide Clinical Development Update
finance.yahoo.com - August 3 at 8:40 AM
finance.yahoo.com logoVerona Pharma to Present at 2017 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 1 at 7:37 AM
nasdaq.com logoVerona Pharma Doses First Patients in Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment - Nasdaq
www.nasdaq.com - July 28 at 9:47 AM
globenewswire.com logoVerona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD ... - GlobeNewswire (press release)
globenewswire.com - June 29 at 3:16 PM
americanbankingnews.com logoN+1 Singer Reaffirms "Corporate" Rating for Verona Pharma Plc (VRP)
www.americanbankingnews.com - June 27 at 10:29 AM
nasdaq.com logoDose escalation trial will evaluate RPL554 as a maintenance treatment in approximately 400 COPD patients
www.nasdaq.com - June 27 at 4:54 AM
nasdaq.com logoVerona Pharma Appoints Dr. Desiree Luthman as Vice President of ... - Nasdaq
www.nasdaq.com - June 22 at 2:37 PM
finance.yahoo.com logoVerona Pharma Appoints Dr. Desiree Luthman as Vice President of Regulatory Affairs
finance.yahoo.com - June 22 at 2:37 PM
americanbankingnews.com logoJefferies Group LLC Reaffirms "Buy" Rating for Verona Pharma Plc (VRP)
www.americanbankingnews.com - June 11 at 12:26 AM
finance.yahoo.com logoVerona Pharma plc : Holding(s) in Company
finance.yahoo.com - June 7 at 12:51 AM
finance.yahoo.com logoVerona Pharma Announces Further Exercise of Over-Allotment Option and Resulting Total Voting Rights
finance.yahoo.com - May 25 at 6:59 AM
finance.yahoo.com logoVerona Pharma to Present at Jefferies 2017 Global Healthcare Conference
finance.yahoo.com - May 23 at 7:58 PM
americanbankingnews.com logoJefferies Group LLC Initiates Coverage on Verona Pharma Plc (VRP)
www.americanbankingnews.com - May 22 at 9:34 PM
americanbankingnews.com logoVerona Pharma Plc (VRP) Earns Buy Rating from Analysts at SunTrust Banks, Inc.
www.americanbankingnews.com - May 22 at 2:00 PM
americanbankingnews.com logoVerona Pharma Plc (VRP) Now Covered by Wedbush
www.americanbankingnews.com - May 22 at 1:24 PM
americanbankingnews.com logoVerona Pharma Plc (VRP) Earns Buy Rating from Analysts at Stifel Nicolaus
www.americanbankingnews.com - May 22 at 9:04 AM
globenewswire.com logoVerona Pharma Announces Closing of Exercise of Underwriters' Over-allotment Option - GlobeNewswire (press release)
globenewswire.com - May 19 at 1:40 PM
finance.yahoo.com logoVerona Pharma Announces Closing of Exercise of Underwriters’ Over-allotment Option
finance.yahoo.com - May 19 at 1:40 PM
businesswire.com logoCiti Appointed Depositary Bank for Verona Pharma’s ADR Programme
www.businesswire.com - May 3 at 6:52 PM
finance.yahoo.com logoGrant of Options and RSUs and PDMR Dealings
finance.yahoo.com - May 3 at 6:52 PM
finance.yahoo.com logoVerona Pharma Announces Closing of Global Offering
finance.yahoo.com - May 2 at 6:38 PM
americanbankingnews.com logoVerona Pharma Plc (VRP) Insider Buys £17,652.36 in Stock
www.americanbankingnews.com - May 1 at 7:12 AM
americanbankingnews.com logoVerona Pharma Plc (VRP) Insider Purchases £300,441.44 in Stock
www.americanbankingnews.com - May 1 at 7:11 AM
globenewswire.com logoVerona Pharma Announces Pricing of Global Offering and Approval to List on the NASDAQ Global Market - GlobeNewswire (press release)
globenewswire.com - April 28 at 10:35 AM
finance.yahoo.com logoVerona Pharma Announces Pricing of Global Offering and Approval to List on the NASDAQ Global Market
finance.yahoo.com - April 27 at 11:48 AM
finance.yahoo.com logoVerona Pharma, Cloudera And 6 Others To Launch IPOs This Week
finance.yahoo.com - April 27 at 11:48 AM
finance.yahoo.com logo[$$] Investor appetite for high-growth IPOs to be tested
finance.yahoo.com - April 25 at 7:30 PM
americanbankingnews.com logoVerona Pharma Plc (VRP) Given  Corporate Rating at N+1 Singer
www.americanbankingnews.com - April 19 at 11:24 AM
americanbankingnews.com logoVerona Pharma Plc (VRP) Receives "corporate" Rating from N+1 Singer
www.americanbankingnews.com - April 8 at 7:58 PM
lse.co.uk logoVerona Pharma Share Chat
www.lse.co.uk - April 1 at 9:48 AM
americanbankingnews.com logoVerona Pharma Plc (VRP) Receives Corporate Rating from N+1 Singer
www.americanbankingnews.com - March 22 at 2:52 PM
uk.finance.yahoo.com logo2 hot growth stocks to buy today on impressive results?
uk.finance.yahoo.com - February 27 at 8:23 AM
lse.co.uk logoResult of General Meeting and Share Consolidation - London South East (registration) (blog)
www.lse.co.uk - February 10 at 6:30 AM
lse.co.uk logoPublication of Circular - London South East (registration) (blog)
www.lse.co.uk - January 18 at 3:45 PM
biz.yahoo.com logoHalf Year 2016 Verona Pharma PLC Earnings Release - Time Not Supplied
biz.yahoo.com - September 13 at 7:20 AM
biz.yahoo.com logoHalf Year 2016 Verona Pharma PLC Earnings Release - Before Market Open
biz.yahoo.com - August 10 at 11:25 AM
finanznachrichten.de logoVERONA PHARMA PLC - Grant of Share Options
www.finanznachrichten.de - August 4 at 11:27 AM
finanznachrichten.de logoVERONA PHARMA PLC - Notice of GM
www.finanznachrichten.de - July 2 at 10:43 AM

Social

Social activity is not available for this stock.

Chart

Verona Pharma Plc (VRP) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff